Alteogen signs $365m Hybrozyme licensing deal with pharma company
South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide…
All articles by Salong Debbarma
Salong Debbarma
-
-
Schrödinger and BMS expand partnership to deploy AI for drug discovery
Schrödinger has entered a strategic agreement with Bristol Myers Squibb (BMS) to integrate its AI-based co-scientist platform Bunsen into BMS’s…
-
AsymBio to secure $184m to support growth in biologics manufacturing
Biologics contract development and manufacturing organisation (CDMO) AsymBio is set to secure 1.2397bn yuan (approximately $184m) from Asymchem Group, Hillhouse…
-
Phylo and Chugai collaborate to deploy AI platform in drug discovery
Phylo has entered a collaboration with Japan-based company Chugai Pharmaceutical to implement Biomni Lab, an agentic AI platform designed for…
-
FDA grants breakthrough therapy designation to Lilly’s olomorasib
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Eli Lilly and Company’s (Lilly) olomorasib as…
-
Curium to acquire Lantheus in all-cash deal worth up to $8bn
CapVest Partners-backed Curium has agreed to buy rival US-based radiopharmaceutical company Lantheus in an all-cash deal worth up to nearly…
-
IMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib
China-based IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to €423.5m ($488.3m), giving Pharmanovia rights to…
-
Ratio Therapeutics secures $70m Series C funding for cancer radiotherapy
Ratio Therapeutics, a US-based clinical-stage developer of radiopharmaceuticals for cancer treatment, has closed a $70m Series C financing round. The…
-
miRecule and Rio Biofarma to develop RNA therapeutic delivery technologies
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at…
-
Resilience and Lilly to increase US medicines production with $750m investment
Resilience and Eli Lilly and Company have expanded their partnership with a joint $750m investment to increase the production of…